- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07454148
Estudio Prospectivo CART-BP para el Control de la Hipertensión
Eficacia y Seguridad del Manejo de la Presión Arterial Guiado por CART BP en Pacientes Coreanos con Hipertensión No Controlada: Un Estudio Prospectivo No Aleatorizado
This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.
The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.
The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Choose One...
-
Seoul, Choose One..., Corea del Sur, 02841
- Korea University Anam Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age >= 19 years
- Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
- Able and willing to provide written informed consent and comply with follow-up visits
Exclusion Criteria:
- History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
- Suspected secondary hypertension
- Atrial fibrillation
- Pregnancy or lactation
- Other serious medical condition that may interfere with study participation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: CART BP pro-guided management
Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data. |
Wearable cuffless continuous blood pressure monitoring device. |
|
Comparador activo: Usual care
Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice. |
Standard hypertension management based on office blood pressure. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
24-hour mean systolic blood pressure
Periodo de tiempo: 24 weeks
|
Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks. |
24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAE)
Periodo de tiempo: 24 weeks
|
Proportion of participants experiencing TEAEs during the 24-week study period. |
24 weeks
|
|
24-hour blood pressure load
Periodo de tiempo: 24 weeks
|
Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours. |
24 weeks
|
|
Office blood pressure change
Periodo de tiempo: 24 weeks
|
Change in office systolic and diastolic blood pressure from baseline to 24 weeks. |
24 weeks
|
|
Target blood pressure achievement rate
Periodo de tiempo: 24 weeks
|
Proportion of participants achieving prespecified ambulatory BP targets. |
24 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CARTBP-HTN-P1-2025
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .